03.29.19
New research from Marshall University links walnut consumption as a contributing factor that could suppress growth and survival of breast cancers.
Led by W. Elaine Hardman, PhD, a professor in the Department of Biomedical Sciences at the Marshall University Joan C. Edwards School of Medicine, a Marshall University team revealed that consumption of two ounces of walnuts a day for about two weeks significantly changed gene expression in confirmed breast cancers. This pilot, two-arm clinical trial is the latest of a series of related studies at Marshall University related to dietary walnut links to tumor growth, survival, and metastasis in breast cancer. The work is described in a March 10 paper published in the journal Nutrition Research.
"Consumption of walnuts has slowed breast cancer growth and/or reduced the risk of mammary cancer in mice," Hardman said. "Building on this research, our team hypothesized that walnut consumption would alter gene expression in pathologically-confirmed breast cancers of women in a direction that would decrease breast cancer growth and survival."
In this first clinical trial, women with breast lumps large enough for research and pathology biopsies were recruited and randomized to walnut consuming or control groups. Immediately following biopsy collection, women in the walnut group began to consume two ounces of walnuts per day until follow-up surgery. Pathological studies confirmed that lumps were breast cancer in all women who remained in the trial. At surgery, about two weeks after biopsy, additional specimens were taken from the breast cancers.
Changes in gene expression in the surgical specimen compared to baseline were determined in each individual woman in walnut-consuming (n = 5) and control (n = 5) groups. RNA sequencing expression profiling revealed that expression of 456 identified genes was significantly changed in the tumor due to walnut consumption. Ingenuity Pathway Analysis showed activation of pathways that promote apoptosis and cell adhesion and inhibition of pathways that promote cell proliferation and migration.
"These results support the hypothesis that, in humans, walnut consumption could suppress growth and survival of breast cancers," Hardman said. "Additional research through a larger-scale study would be needed to clinically confirm that walnut consumption actually does reduce the risk of breast cancer or breast cancer recurrence."
This study is an example of the critical role of a team in modern research. Breast surgeons Mary Legenza, MD, of Marshall University Joan C. Edwards School of Medicine and Edwards Comprehensive Cancer Center, and James Morgan, MD, formerly of St. Mary's Medical Center, collected biopsies from patient volunteers for the clinical trial. Donald A. Primerano, PhD, Jun Fan, PhD, and James Denvir, PhD, of the Genomics and Bioinformatics Core Facility at Marshall University Joan C. Edwards School of Medicine performed the RNA expression profiling, bioinformatic and statistical analyses.
The study was funded, in part, by the California Walnut Commission (CWC), which provided the walnuts and necessary funding. The CWC did not influence the development of the study, analyses of the data or decision to publish the results. All data is available online. The National Institutes of Health also provided funding via support of Gary Rankin, PhD, via the Genomics Core at Marshall University (NIH/NIGMS P20GM103434) and support to Drs. Denvir, Hardman and Primerano, via the Center of Biomedical Research Excellence at Marshall University (NIH/NIGMS P20GM121299).
Led by W. Elaine Hardman, PhD, a professor in the Department of Biomedical Sciences at the Marshall University Joan C. Edwards School of Medicine, a Marshall University team revealed that consumption of two ounces of walnuts a day for about two weeks significantly changed gene expression in confirmed breast cancers. This pilot, two-arm clinical trial is the latest of a series of related studies at Marshall University related to dietary walnut links to tumor growth, survival, and metastasis in breast cancer. The work is described in a March 10 paper published in the journal Nutrition Research.
"Consumption of walnuts has slowed breast cancer growth and/or reduced the risk of mammary cancer in mice," Hardman said. "Building on this research, our team hypothesized that walnut consumption would alter gene expression in pathologically-confirmed breast cancers of women in a direction that would decrease breast cancer growth and survival."
In this first clinical trial, women with breast lumps large enough for research and pathology biopsies were recruited and randomized to walnut consuming or control groups. Immediately following biopsy collection, women in the walnut group began to consume two ounces of walnuts per day until follow-up surgery. Pathological studies confirmed that lumps were breast cancer in all women who remained in the trial. At surgery, about two weeks after biopsy, additional specimens were taken from the breast cancers.
Changes in gene expression in the surgical specimen compared to baseline were determined in each individual woman in walnut-consuming (n = 5) and control (n = 5) groups. RNA sequencing expression profiling revealed that expression of 456 identified genes was significantly changed in the tumor due to walnut consumption. Ingenuity Pathway Analysis showed activation of pathways that promote apoptosis and cell adhesion and inhibition of pathways that promote cell proliferation and migration.
"These results support the hypothesis that, in humans, walnut consumption could suppress growth and survival of breast cancers," Hardman said. "Additional research through a larger-scale study would be needed to clinically confirm that walnut consumption actually does reduce the risk of breast cancer or breast cancer recurrence."
This study is an example of the critical role of a team in modern research. Breast surgeons Mary Legenza, MD, of Marshall University Joan C. Edwards School of Medicine and Edwards Comprehensive Cancer Center, and James Morgan, MD, formerly of St. Mary's Medical Center, collected biopsies from patient volunteers for the clinical trial. Donald A. Primerano, PhD, Jun Fan, PhD, and James Denvir, PhD, of the Genomics and Bioinformatics Core Facility at Marshall University Joan C. Edwards School of Medicine performed the RNA expression profiling, bioinformatic and statistical analyses.
The study was funded, in part, by the California Walnut Commission (CWC), which provided the walnuts and necessary funding. The CWC did not influence the development of the study, analyses of the data or decision to publish the results. All data is available online. The National Institutes of Health also provided funding via support of Gary Rankin, PhD, via the Genomics Core at Marshall University (NIH/NIGMS P20GM103434) and support to Drs. Denvir, Hardman and Primerano, via the Center of Biomedical Research Excellence at Marshall University (NIH/NIGMS P20GM121299).
